{"id":21789,"date":"2026-02-23T11:30:09","date_gmt":"2026-02-23T11:30:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/21789\/"},"modified":"2026-02-23T11:30:09","modified_gmt":"2026-02-23T11:30:09","slug":"novo-nordisk-stock-hits-52-week-low-heres-why-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/21789\/","title":{"rendered":"Novo Nordisk Stock Hits 52-Week Low – Here’s Why – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

Novo Nordisk A\/S (NYSE:<\/a>NVO<\/a>) stock is plunging on Monday on disappointing headline data from its REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial program.<\/p>\n

After the update, Novo Nordisk stock hit its 52-week low. Over the year, the stock has fallen around 48%, according to Benzinga Pro data<\/a>.<\/p>\n

The 809-subject REDEFINE 4 was an 84-week trial investigating CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to tirzepatide 15 mg, both administered once weekly and subcutaneously.<\/p>\n

Eli Lilly and Co.\u2019s (NYSE:<\/a>LLY<\/a>) tirzepatide is marketed under the Zepbound and Mounjaro brands.<\/p>\n

Efficacy Results: CagriSema vs. Tirzepatide<\/p>\n

When applying the treatment regimen estimand, people treated with CagriSema 2.4 mg\/2.4 mg achieved a weight loss<\/a> of 20.2% compared to 23.6% with tirzepatide at 84 weeks.<\/p>\n

The trial did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks.<\/p>\n

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common\u00a0adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.<\/p>\n

Management Commentary<\/p>\n

\u201cBased on the learnings from completed studies, we look forward to the REDEFINE 11 readout and the initiation of the higher-dose CagriSema trial, which are both designed to assess the full weight-loss potential of CagriSema\u201d, said Martin Holst Lange, executive vice president, R&D and chief scientific officer at Novo Nordisk.<\/p>\n

The REDEFINE 11 phase 3 trial exploring CagriSema 2.4\/2.4 mg full weight-loss potential in obesity is expected to report data during the first half of 2027, while initiation of the phase 3 CagriSema higher-dose trial is planned for the second half of 2026.<\/p>\n

In February, Novo Nordisk shared headline results from the REIMAGINE 2 phase 3 trial of CagriSema, demonstrating higher HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial<\/a>.<\/p>\n

NVO Price Action: Novo Nordisk shares were down 13.29% at $41.12 during premarket trading on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data<\/a>.<\/p>\n

Image via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) stock is plunging on Monday on disappointing headline data from its REDEFINE 4, an…\n","protected":false},"author":2,"featured_media":10471,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2092,2088,5813,2084,272,352,8257,2096,2099,2100],"class_list":{"0":"post-21789","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-movers","13":"tag-category-news","14":"tag-category-top-stories","15":"tag-cms-wordpress","16":"tag-novo-nordisk","17":"tag-pageisbzpro-bz","18":"tag-symbol-lly","19":"tag-symbol-nvo","20":"tag-tag-weight-loss","21":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/21789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=21789"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/21789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/10471"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=21789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=21789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=21789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}